| Name | Title | Contact Details |
|---|---|---|
Chi-Kai Chien |
VP, Engineering | Profile |
Tom Brandl |
Chief Information Security Officer | Profile |
Pathfinder Solutions is a company that provides a fully integrated technology tool that enables connection and collaboration with individuals and their support teams for addiction and substance use disorder recovery.
Our revolutionary technology is radically different than any other form of automated medical billing software or revenue cycle management. Unlike a PMS vendor or a clearinghouse, the Encoda BackOffice suite of products enhances and improves existing billing systems and billing service providers’ operations, making them more intelligent. The difference? On average, our customers increase staff productivity by more than 30% and dramatically reduce operating expenses, helping their practices to grow. How do we do this? We apply business intelligence and programming logic tools from the high-tech community to healthcare, and pass those technological advantages on to medical business offices. In adding this advanced technology to our clients’ systems, we create a direct connection between clients and payers, seamlessly integrating the two environments eliminating the need for human intervention.
We remain closely connected to the citizens we serve through responsive and timely communication, and we deeply value our role as a trusted source of information regarding health and senior issues.
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to surgery.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.